Study protocol--metabolic syndrome, vitamin D and bone status in South Asian women living in Auckland, New Zealand: a randomised, placebo-controlled, double-blind vitamin D intervention

von Hurst, Pamela R.; Stonehouse, Welma; Matthys, Christophe; Conlon, Cathryn; Kruger, Marlena C.; Coad, Jane
January 2008
BMC Public Health;2008, Vol. 8 Issue 1, p267
Academic Journal
Background: The identification of the vitamin D receptor in the endocrine pancreas suggests a role for vitamin D in insulin secretion. There is also some limited evidence that vitamin D influences insulin resistance, and thus the early stages of the development of type 2 diabetes. Methods: Eighty-four women of South Asian origin, living in Auckland, New Zealand, were randomised to receive either a supplement (4000IU 25(OH)D3 per day) or a placebo for 6 months. At baseline, all participants were vitamin D deficient (serum 25(OH)D3 <50 nmol/L), insulin resistant (HOMA-IR > 1.93) and/or hyperinsulinaemic, hyperglycemic or had clinical signs of dislipidaemia. Changes in HOMA-IR, lipids, parathyroid hormone, calcium and bone markers were monitored at 3 months and 6 months. Discussion: This randomised, controlled trial will be the first to investigate the effect of vitamin D supplementation on insulin resistance in non-diabetic subjects. It will subsequently contribute to the growing body of evidence about the role of vitamin D in metabolic syndrome. Registered clinical. Trial registration: Registered clinical trial - Registration No. ACTRN12607000642482


Related Articles

  • Tight glycaemic control and cardiovascular disease in type 2 diabetes. Demssie, Yared N.; Soran, Handrean; Younis, Naveed // British Journal of Hospital Medicine (17508460);Jan2009, Vol. 70 Issue 1, p31 

    The role of tight glycaemic control in reducing cardiovascular events and mortality in type 2 diabetes has not yet been firmly established. Recent clinical trials have yielded unexpected outcomes. This review summarizes the background and outcome of these trials and the implications for...

  • Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy. Derosa, Giuseppe; Salvadeo, Sibilla Anna Teresa // Core Evidence;2007, Vol. 2 Issue 3, p189 

    Introduction: Type 2 diabetes mellitus, a metabolic disease with increasing incidence, is one of the most important cardiovascular risk factors. Insulin resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Metformin and the thiazolidinediones, pioglitazone...

  • Validation of two generic patient-reported outcome measures in patients with type 2 diabetes. Matza, Louis S.; Boye, Kristina S.; Yurgin, Nicole // Health & Quality of Life Outcomes;2007, Vol. 5, p47 

    Background: Prior to using a generic patient-reported outcome measure (PRO), the measure should be validated within the target population. The purpose of the current study was to validate two generic measures in patients with type 2 diabetes. Methods: Patients with type 2 diabetes in Scotland...

  • Roles of Oxidants, Nitric Oxide, and Asymmetric Dimethylarginine in Endothelial Function. Siekmeier, Rüdiger; Grammer, Tanja; März, Winfried // Journal of Cardiovascular Pharmacology & Therapeutics;Dec2008, Vol. 13 Issue 4, p279 

    The article discusses clinical studies made on the effects of reactive oxygen species (ROS), nitric oxide (NO) and asymmetric dimethylarginine (ADMA) in treating endothelial dysfunction which causes atherosclerotic vascular diseases. Studies show that the use of the mentioned agents alone cannot...

  • Metformin Extended Release.  // Drugs in R&D;2005, Vol. 6 Issue 5, p316 

    Metformin extended release [Glumetzaâ„¢, metformin hydrochloride, metformin gastric retention, metformin GRâ„¢] is a proprietary once-a-day formulation of metformin hydrochloride under development with Depomed for the treatment of diabetes mellitus. In May 2002, Depomed licensed...

  • Global standardisation of HbA1c. Lai, Leslie C. // Malaysian Journal of Pathology;Dec2008, Vol. 30 Issue 2, p67 

    HbA1c is used for assessing glycaemic control in patients with diabetes. It is also used for treatment goals and as a target for therapeutic intervention. The Direct Control and Complications Trial in the USA showed that HbA1c can be used to predict the risk of complications. Hence, it is...

  • Errata.  // Diabetes;Mar2006, Vol. 55 Issue 3, p862 

    Corrections to articles in previous issues including a research on diabetes-accelerated atherosclerosis in the 2004 issue and a study on resistance to diet-induced obesity in the 2005 issue are presented.

  • Study to Leverage iPads for Diabetes Interventions. Goth, Greg // Healthdatamanagement.com;8/25/2014, p1 

    The article reports on the partnerships between North Carolina Translational and Clinical Sciences Institute and South Carolina Clinical and Translational Research Institute to conduct a study regarding ways on how to reduce diabetes prevalence and complications in Bamberg County, South Carolina.

  • Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues. Brod, Meryl; Cobden, David; Lammert, Morten; Bushnell, Donald; Raskin, Philip // Health & Quality of Life Outcomes;2007, Vol. 5, p8 

    Background: Successfully managing diabetes is a complex process that includes addressing issues of drug efficacy, safety and treatment satisfaction. Additionally, the combined impact of patient/ disease characteristics and treatment outcomes on treatment satisfaction is not well understood. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics